Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea · Delayed Price · Currency is KRW 102,600
-400 (-0.39%)
Jun 12, 2026, 3:30 PM KST
Kolon TissueGene Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,281 | 5,159 | 5,073 | 3,706 | 9,456 | 4,003 | |
Revenue Growth (YoY) | 2.95% | 1.68% | 36.90% | -60.81% | 136.22% | 12.58% |
Cost of Revenue | 4,650 | 4,544 | 4,528 | 3,340 | 1,811 | 3,611 |
Gross Profit | 630.9 | 614.5 | 545.13 | 365.92 | 7,645 | 392.15 |
Selling, General & Admin | 15,333 | 13,343 | 15,849 | 13,679 | 14,694 | 15,906 |
Research & Development | 6,530 | 8,549 | 5,612 | 5,635 | 7,123 | 29,890 |
Amortization of Goodwill & Intangibles | 29.53 | 29.7 | 39.95 | 113.74 | 98.19 | 87.7 |
Other Operating Expenses | 180.62 | 237.61 | 269.39 | 173.93 | 224.81 | 56.02 |
Operating Expenses | 22,914 | 22,938 | 22,543 | 20,877 | 23,953 | 47,493 |
Operating Income | -22,284 | -22,323 | -21,998 | -20,511 | -16,308 | -47,101 |
Interest Expense | -101.9 | -89.6 | -89.85 | -285.82 | -371.18 | -466.46 |
Interest & Investment Income | 2,223 | 1,760 | 1,040 | 2,221 | 670.49 | 129.69 |
Currency Exchange Gain (Loss) | 4,266 | 787.43 | 813.15 | 256.82 | 1,512 | 50.89 |
Other Non Operating Income (Expenses) | -270,756 | -172,739 | -13,661 | 1,351 | 4,676 | 249.99 |
EBT Excluding Unusual Items | -286,652 | -192,604 | -33,895 | -16,968 | -9,821 | -47,136 |
Gain (Loss) on Sale of Assets | 38.6 | 37.35 | 1.02 | -3.43 | - | -14.87 |
Pretax Income | -286,614 | -192,567 | -33,894 | -16,971 | -9,821 | -47,151 |
Income Tax Expense | 20.62 | 20.94 | -95.47 | 253.15 | 1,316 | 218.27 |
Net Income | -286,634 | -192,587 | -33,799 | -17,224 | -11,136 | -47,370 |
Net Income to Common | -286,634 | -192,587 | -33,799 | -17,224 | -11,136 | -47,370 |
Shares Outstanding (Basic) | 83 | 82 | 77 | 72 | 66 | 61 |
Shares Outstanding (Diluted) | 83 | 82 | 77 | 72 | 66 | 61 |
Shares Change (YoY) | 5.95% | 6.78% | 7.32% | 8.18% | 8.25% | 0.29% |
EPS (Basic) | -3456.66 | -2343.80 | -439.20 | -240.20 | -168.00 | -773.60 |
EPS (Diluted) | -3456.66 | -2343.80 | -439.20 | -240.20 | -168.00 | -773.60 |
Free Cash Flow | -12,510 | -25,210 | -20,581 | -24,370 | -26,844 | -40,568 |
Free Cash Flow Per Share | -150.87 | -306.81 | -267.44 | -339.84 | -404.97 | -662.52 |
Gross Margin | 11.95% | 11.91% | 10.75% | 9.87% | 80.85% | 9.80% |
Operating Margin | -421.96% | -432.73% | -433.58% | -553.45% | -172.46% | -1176.59% |
Profit Margin | -5427.70% | -3733.25% | -666.19% | -464.76% | -117.77% | -1183.31% |
Free Cash Flow Margin | -236.90% | -488.69% | -405.66% | -657.56% | -283.88% | -1013.40% |
EBITDA | -21,433 | -21,539 | -21,189 | -19,099 | -14,643 | -45,550 |
EBITDA Margin | - | - | - | - | -154.85% | - |
D&A For EBITDA | 850.6 | 784.02 | 808.55 | 1,412 | 1,665 | 1,551 |
EBIT | -22,284 | -22,323 | -21,998 | -20,511 | -16,308 | -47,101 |
EBIT Margin | - | - | - | - | -172.46% | - |
Advertising Expenses | - | 19.35 | 37.32 | 11.48 | 0.5 | 18.66 |